Anavex CEO to Present Clinical Prediction Data for ANAVEX 2-73 at CNS Summit 2013
New York, NY — November 7, 2013 — Anavex Life Sciences Corp. (OTCQB: AVXL) is pleased to announce that its President and Chief Executive Officer Christopher U. Missling, PhD, will be presenting new clinical predication data supporting its investigational compound, ANAVEX 2-73, as a potential therapeutic for the treatment of Alzheimer’s disease. The data will be unveiled in a poster presentation at the CNS Summit 2013, which takes place November 14-17, 2013 in Boca Raton, Florida. The poster presentation was co-authored by Tangui Maurice, PhD, INSERM; Athan Spiros, In Silico BioSciences (ISB); Patrick Roberts, ISB and Oregon Health & Science University; and, Hugo Geerts, ISB and University of Pennsylvania.
The findings will be presented during the following poster session:
|Title:||The anticipated clinical effect of the new Alzheimer drug ANAVEX 2-73 in a calibrated Quantitative Systems Pharmacology Platform|
|Date:||Saturday, November 16, 2013|
|Time:||5:00 PM – 7:00 PM ET|
|Place:||The Boca Raton Waldorf Astoria
501 East Camino Real, Boca Raton, FL 33432
ANAVEX 2-73 is an orally available small molecule being investigated for the treatment of Alzheimer’s disease. In addition to pre-clinical data indicating that ANAVEX 2-73 has the potential to prevent, halt and/or reverse the course of Alzheimer’s disease, there was also a highly encouraging synergistic effect observed between ANAVEX 2-73 and Aricept® (donepezil). The combined therapeutics produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s, CNS diseases and various types of cancer. ANAVEX 2-73, a drug candidate developed to treat Alzheimer’s through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg. Results from pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties. Anavex is a publicly traded corporation quoted as AVXL.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information
Anavex Life Sciences Corp.
Research & Business Development